Linda L Garland, MD

Associate Professor of Clinical Medicine

Director Clinical Lung Cancer Program

Full Investigator/Cancer Prevention and Control Program

E-Mail Address: 
lgarland@azcc.arizona.edu
Phone Number: 
520-626-3434
Fax: 
520-626-3434
Short Bio: 

Dr Garland's clinical and research interests are in experimental therapeutics, with a focus on malignant diseases of the chest.  These include lung cancer, mesothelioma and rarer mediastinal tumors.

Clinical Information
Specialty: 
Medical Oncologist
Clinical Focus: 

Non-small cell lung cancer, small cell lung cancer, mesothelioma, head and neck cancer, thyroid cancer.

Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
4. Cancer Prevention and Control
Member Status: 
Associate Member
Summary of Research Activity: 

My clinical and research interests are in experimental therapeutics, with a focus on malignant diseases of the chest.  These include lung cancer, mesothelioma, and rarer mediastinal tumors.  In general, both small cell and non-small cell lung cancers are difficult to diagnose at an early stage, once advanced, they are highly lethal malignancies.  Standard chemotherapy offers palliative benefit, but only limited survival benefit for lung cancer patients. 

Novel targets for therapeutic design, including targets in signal transduction pathways and in pathways conferring drug resistance, are being identified.  We are designing trials using new chemotherapy agents and small molecules that are able to inhibit more selectively the activity of these targets, thus providing more potent anticancer activity with less normal tissue toxicity.

Appropriate targets in an individual lung cancer patient's tumor may be able to be defined using molecular biologic assays of tumor tissue, therefore allowing more finely tuned therapy for that individual.

 

Selected Publications: 

Garland L, Taylor C, Pilkington D, Cohen J, Von Hoff D. A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative With Polo-Like Kinase-1 Interacting Properties, in Patients With Advanced Solid Tumors. Clin Cancer Res 2006:12;5182-9.

Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R, Altomare D, Klein-Szanto A, Testa R, Borden E. A Phase II study of oral EGFR tyrosine kinase inhibitor erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol 2007:25;2406-2413.

Herbst RS, Davies A, Natale R, Dang T, Murren J, Schiller J, Garland L, Miller V, Mendelson D, Van den Abbeele A, Melenevsky Y, de Vries D, Eberhard D, Lyons B, Lutzker S, Johnson BE. Efficacy and Safety of Single Agent Pertuzumab, a HER Dimerization Inhibitor, in Patients with Non–Small-Cell Lung Cancer. Clin Cancer Res 2007:13;6175-81.

Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vincent V. Can Stereotactic Fractionated Radiation Therapy Become the Standard of Care for Early-Stage Non-Small Cell Lung Cancer? Cancer Treat Rev 2008;34(8):719-27.
 

Professional Information
Board Certifications: 

American Board of Medical Oncology

Academic Information
Fellowship: 
H. Lee Moffitt Cancer Center (Hematology/Oncology) 1996
Residency: 
University of South Florida College of Medicine (Internal Medicine) 1993
Medical School: 
University of Texas Health Science Center, 1988